PMID- 37919738
OWN - NLM
STAT- MEDLINE
DCOM- 20231106
LR  - 20231113
IS  - 1743-422X (Electronic)
IS  - 1743-422X (Linking)
VI  - 20
IP  - 1
DP  - 2023 Nov 2
TI  - The efficacy and safety assessment of oncolytic virotherapies in the treatment of 
      advanced melanoma: a systematic review and meta-analysis.
PG  - 252
LID - 10.1186/s12985-023-02220-x [doi]
LID - 252
AB  - BACKGROUND: The efficacy and safety of oncolytic virotherapies in the treatment 
      of advanced melanoma still remains controversal. It is necessary to conduct 
      quantitative evaluation on the basis of preclinical trial reports. METHODS: 
      Publicly available databases (PubMed, Embase, Medline, Web of Science and 
      Cochrane Library.) and register (Clinicaltrials.gov) were searched to collect 
      treatment outcomes of oncolytic virotherapies (including herpes simplex virus 
      type 1 (HSV), coxsackievirus A21 (CVA21), adenovirus, poxvirus and reovirus) for 
      advanced/unresectable melanoma. Comparisons of treatment response, adverse events 
      (AEs) and survival analyses for different virotherapies were performed by R 
      software based on the extracted data from eligible studies. RESULTS: Finally, 
      thirty-four eligible studies were analysed and HSV virotherapy had the highest 
      average complete response (CR, 24.8%) and HSV had a slightly higher average 
      overall response rate (ORR) than CVA21 (43.8% vs 42.6%). In the pooled results of 
      comparing talimogene laherparepve (T-VEC) with or without GM-CSF/ICIs (immune 
      checkpoint inhibitors) to GM-CSF/ICIs monotherapy suggested virotherapy was more 
      efficient in subgroups CR (RR = 1.80, 95% CI [1.30; 2.51], P < 0.01), ORR 
      (RR = 1.17, 95% CI [1.02; 1.34], P < 0.05), and DCR (RR = 1.27, 95% CI [1.15; 
      1.40], P < 0.01). In patients treated with T-VEC+ICIs, 2-year overall survival 
      (12.1 +/- 6.9 months) and progression-free survival (9.9 +/- 6.9) were significantly 
      longer than those treated with T-VEC alone. Furthermore, we found that AEs 
      occurred frequently in virotherapy but decreased in a large cohort of enrolled 
      patients, some of which, such as abdominal distension/pain, injection site pain 
      and pruritus, were found to be positively associated with disease progression in 
      patients treated with T-VEC monotherapy. CONCLUSION: Given the relative safety 
      and tolerability of oncolytic viruses, and the lack of reports of 
      dose-limiting-dependent toxicities, more patients treated with T-VEC with or 
      without ICIs should be added to future assessment analyses. There is still a long 
      way to go before it can be used as a first-line therapy for patients with 
      advanced or unresectable melanoma.
CI  - (c) 2023. The Author(s).
FAU - Wang, Changyuan
AU  - Wang C
AD  - Department of Dermatology, University of Health and Rehabilitation Sciences 
      (Qingdao Municipal Hospital), NO.1 Jiaozhou Road, Qingdao, 266000, Shandong 
      Province, China.
FAU - Lu, Nanxiao
AU  - Lu N
AD  - Department of Dermatology, University of Health and Rehabilitation Sciences 
      (Qingdao Municipal Hospital), NO.1 Jiaozhou Road, Qingdao, 266000, Shandong 
      Province, China.
FAU - Yan, Lin
AU  - Yan L
AD  - Department of Dermatology, University of Health and Rehabilitation Sciences 
      (Qingdao Municipal Hospital), NO.1 Jiaozhou Road, Qingdao, 266000, Shandong 
      Province, China.
FAU - Li, Yang
AU  - Li Y
AD  - Department of Dermatology, University of Health and Rehabilitation Sciences 
      (Qingdao Municipal Hospital), NO.1 Jiaozhou Road, Qingdao, 266000, Shandong 
      Province, China. 1722040740@stu.cpu.edu.cn.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
DEP - 20231102
PL  - England
TA  - Virol J
JT  - Virology journal
JID - 101231645
RN  - 83869-56-1 (Granulocyte-Macrophage Colony-Stimulating Factor)
SB  - IM
MH  - Humans
MH  - *Oncolytic Virotherapy/adverse effects/methods
MH  - Granulocyte-Macrophage Colony-Stimulating Factor/therapeutic use
MH  - Immunotherapy/methods
MH  - *Melanoma/drug therapy
MH  - *Oncolytic Viruses/genetics
MH  - Pain
PMC - PMC10623758
OTO - NOTNLM
OT  - Advanced melanoma
OT  - Adverse events
OT  - Oncolytic virus
OT  - Overall survival
OT  - Progression-free survival
OT  - Treatment response
OT  - Virotherapy
COIS- All authors declare no conflict of interests.
EDAT- 2023/11/03 06:44
MHDA- 2023/11/06 06:43
PMCR- 2023/11/02
CRDT- 2023/11/03 00:52
PHST- 2023/01/15 00:00 [received]
PHST- 2023/10/28 00:00 [accepted]
PHST- 2023/11/06 06:43 [medline]
PHST- 2023/11/03 06:44 [pubmed]
PHST- 2023/11/03 00:52 [entrez]
PHST- 2023/11/02 00:00 [pmc-release]
AID - 10.1186/s12985-023-02220-x [pii]
AID - 2220 [pii]
AID - 10.1186/s12985-023-02220-x [doi]
PST - epublish
SO  - Virol J. 2023 Nov 2;20(1):252. doi: 10.1186/s12985-023-02220-x.